|
|
|
|
|
|
Late |
JamaliMoghadamSiahkali et al., Research Square, doi:10.21203/rs.3.rs-139942/v1 (Preprint) |
death, 0.0%, p=1.00 |
Safety and Effectiveness of High-Dose Vitamin C in Patients with COVID-19; A Randomized Controlled open-label Clinical Trial |
| Small RCT for the addition of vitamin C to HCQ and lopinavir/ritonavir, not finding significant improvements. Dose was 6g/day. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| JamaliMoghadamSiahkali et al., Research Square, doi:10.21203/rs.3.rs-139942/v1 (Preprint) |
| Safety and Effectiveness of High-Dose Vitamin C in Patients with COVID-19; A Randomized Controlled open-label Clinical Trial |
| Small RCT for the addition of vitamin C to HCQ and lopinavir/ritonavir, not finding significant improvements. Dose was 6g/day.
death, 0.0%, p=1.00
ventilation, ↑25.0%, p=1.00
hospitalization time, ↑30.8%
|
|
Submit Corrections or Comments
|
|
Late |
Kumari et al., Cureus 12(11): e11779, doi:10.7759/cureus.11779 (Peer Reviewed) |
death, ↓36.4%, p=0.45 |
The Role of Vitamin C as Adjuvant Therapy in COVID-19 |
| RCT 150 hospitalized patients in Pakistan showing 26% faster recovery, p < 0.0001. 36% lower mortality, not statistically significant due to the small number of events. Dosage was 50 mg/kg/day of intravenous vitamin C. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Kumari et al., Cureus 12(11): e11779, doi:10.7759/cureus.11779 (Peer Reviewed) |
| The Role of Vitamin C as Adjuvant Therapy in COVID-19 |
RCT 150 hospitalized patients in Pakistan showing 26% faster recovery, p < 0.0001. 36% lower mortality, not statistically significant due to the small number of events. Dosage was 50 mg/kg/day of intravenous vitamin C.
![]()
death, ↓36.4%, p=0.45
ventilation, ↓20.0%, p=0.67
recovery time, ↓26.0%, p<0.0001, days to symptom-free
hospitalization time, ↓24.3%, p<0.0001, days spent in hospital
|
|
Submit Corrections or Comments
|
|
PrEP |
Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1 (Preprint) |
cases, ↓9.6%, p=0.58 |
Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study |
| Retrospective prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.
HCQ OR 0.56, p = 0.29
Ivermectin O.. |
|
Details
Source
PDF
Pre-Exposure Prophylaxis study
Pre-Exposure Prophylaxis study
|
| Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1 (Preprint) |
| Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study |
Retrospective prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.HCQ OR 0.56, p = 0.29
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58
![]()
COVID-19 case, ↓9.6%, p=0.58, Model 2 conditional logistic regression
(odds ratio converted to relative risk)
|
|
Submit Corrections or Comments
|
|
Late |
Zhang et al., Research Square, doi:10.21203/rs.3.rs-52778/v2 (Preprint) |
death, ↓50.0%, p=0.31 |
Pilot Trial of High-dose vitamin C in critically ill COVID-19 patients |
| Small RCT for high dose vitamin C for ICU patients showing reduced (but not statistically significant) mortality. Dosage was 12g of vitamin C/50ml every 12 hours for 7 days at a rate of 12ml/hour. |
|
Details
Source
PDF
Late treatment study
Late treatment study
|
| Zhang et al., Research Square, doi:10.21203/rs.3.rs-52778/v2 (Preprint) |
| Pilot Trial of High-dose vitamin C in critically ill COVID-19 patients |
Small RCT for high dose vitamin C for ICU patients showing reduced (but not statistically significant) mortality. Dosage was 12g of vitamin C/50ml every 12 hours for 7 days at a rate of 12ml/hour.
![]()
death, ↓50.0%, p=0.31, 28 day mortality
death, ↓70.0%, p=0.07, 28 day mortality for SOFA>=3
|
|
Submit Corrections or Comments
|
|
Review |
Feyaerts et al., Nutrition, doi:10.1016/j.nut.2020.110948 (Review) (Peer Reviewed) |
review |
Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? |
| Review concluding that there is clear evidence that vitamin C in high doses can reduce interleukin-6 and endothelin-1 mediators. Authors suggest a relatively low dose as prophylaxis, and in cases of severe COVID-19, an (intravenous) high-.. |
|
Details
Source
PDF
Review
Review
|
| Feyaerts et al., Nutrition, doi:10.1016/j.nut.2020.110948 (Review) (Peer Reviewed) |
| Vitamin C as prophylaxis and adjunctive medical treatment for COVID-19? |
Review concluding that there is clear evidence that vitamin C in high doses can reduce interleukin-6 and endothelin-1 mediators. Authors suggest a relatively low dose as prophylaxis, and in cases of severe COVID-19, an (intravenous) high-dose regimen may be beneficial.
![]()
|
|
Submit Corrections or Comments
|
